| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Condylox Gel Approved by FDA for Genital and Perianal Warts CORONA, Calif., March 17, 1997 -- The U.S. Food and Drug Administration (FDA) has approved to market Condylox(R) Gel 0.5% (podofilox) for the treatment of external genital and perianal warts (condyloma acuminata). The product is expected to be launched in the second quarter of fiscal 1997. It is believed that Condylox(R) Gel offers two important advancements over Condylox topical solution, introducedin 1991: easy, finger-tip application and an expanded perianal wart indication. Oclassen Pharmaceuticals, Inc., a wholly-owned subsidiary of Watson Pharmaceuticals, is dedicated to the development and acquisition of unique proprietary dermatological products. Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is engaged in the manufacture and sale of off-patent medications and branded pharmaceutical products.
|